Company Encyclopedia
View More
name
TAIJI GROUP
600129.SH
Chongqing Taiji Industry(Group) Co.,Ltd, together with its subsidiaries, produces, and sells Chinese and western medicine products in China and internationally. It operates through Pharmaceutical Industry; Pharmaceutical Commercial; Chinese Herbal Medicine Resources; and Service Industry and Others segments. The company offers digestive system and metabolic, respiratory system, cardiovascular and cerebrovascular, anti-infective, nervous system, and anti-tumor and immunomodulatory drugs; anti-aging; and health products. It also engages in accommodation, loading and unloading, warehousing, catering, retail, agriculture, wholesale, and aquaculture activities; and research and development of medicinal herb planting.
3.157 T
600129.SHMarket value -Rank by Market Cap -/-

Financial Score

05/12/2025 Update
D
PharmaceuticalsIndustry
Industry Ranking185/223
Industry medianC
Industry averageC
Score Analysis
Peer Comparison
  • Criteria
    Rating
  • Profit ScoreD
    • ROE-9.35%D
    • Profit Margin-3.51%D
    • Gross Margin30.56%C
  • Growth ScoreE
    • Revenue YoY-27.63%E
    • Net Profit YoY-157.88%E
    • Total Assets YoY-0.78%D
    • Net Assets YoY-10.95%D
  • Cash ScoreE
    • Cash Flow Margin-2848.07%E
    • OCF YoY-27.63%E
  • Operating ScoreB
    • Turnover0.7B
  • Debt ScoreD
    • Gearing Ratio74.16%D

Valuation analysis

portai
P/E
1Y
3Y
5Y
10Y
P/E
-
Industry Ranking
-/-
  • P/E
  • Price
  • High
  • Median
  • Low
P/B
1Y
3Y
5Y
10Y
P/B
-
Industry Ranking
-/-
  • P/B
  • Price
  • High
  • Median
  • Low
P/S
1Y
3Y
5Y
10Y
P/S
-
Industry Ranking
-/-
  • P/S
  • Price
  • High
  • Median
  • Low
Dividend Yield
1Y
3Y
5Y
10Y
Dividend Yield
-
Industry Ranking
-/-
  • Dividend Yield
  • Price
  • High
  • Median
  • Low

Institutional View & Shareholder

Analyst Ratings

Rating
Percentage
    • Price
      --
    • Highest
      --
    • Lowest
      --
    News
    View More

    TAIJI GROUP released its performance for the first three quarters, with a net profit attributable to the parent company of 166 million yuan, a year-on-year decrease of 69.56%

    According to the Zhitong Finance APP, TAIJI GROUP disclosed its third-quarter report for 2025. The company achieved a revenue of 8.088 billion yuan in the first three quarters, a year-on-year decrease of 22.49%; the net profit attributable to the parent company was 166 million yuan, a year-on-year decrease of 69.56%; the net profit excluding non-recurring gains and losses was 90.84 million yuan, a year-on-year decrease of 81.85%; and the basic earnings per share were 0.30 yuan

    Zhitong·
    SH
    600129
    +0.37%
    Zhitong·
    SH
    600129
    +0.37%

    TAIJI GROUP: Received the clinical trial approval notice for Semaglutide injection

    TAIJI GROUP's wholly-owned subsidiary Fuling Pharmaceutical Factory recently received approval from the National Medical Products Administration to conduct clinical trials for Semaglutide injection, indicated for type 2 diabetes. This medication is a long-acting GLP-1 receptor agonist that stimulates insulin production, inhibits glucagon secretion, and reduces appetite, assisting in weight management

    Zhitong·
    SH
    600129
    +0.37%
    Zhitong·
    SH
    600129
    +0.37%

    TAIJI GROUP: The frozen amount in the subsidiary's bank account has decreased from 62.9212 million yuan to 20 million yuan

    TAIJI GROUP announced that its holding subsidiary, Southwest Pharmaceutical, has had the amount of frozen funds in some bank accounts reduced from RMB 62.9212 million to RMB 20 million due to a sales contract dispute. The funds of RMB 42.9212 million frozen in the case of the sales contract dispute between Tibet Huiye Pharmaceutical Technology Co., Ltd. and Southwest Pharmaceutical have all been unfrozen, and the bank accounts have resumed normal use. The freezing of bank account funds during this period did not have a significant impact on the company's main operations

    Zhitong·
    SH
    600129
    +0.37%
    Zhitong·
    SH
    600129
    +0.37%

    TAIJI GROUP released its performance for the first half of the year, with a net profit attributable to the parent company of 139 million yuan, a year-on-year decrease of 71.94%

    According to the Zhitong Finance APP, TAIJI GROUP released its semi-annual report for 2025. During the reporting period, the company achieved operating revenue of 5.658 billion yuan, a year-on-year decrease of 27.63%. The net profit attributable to shareholders of the listed company was 139 million yuan, a year-on-year decrease of 71.94%. The net profit attributable to shareholders of the listed company after deducting non-recurring gains and losses was 120 million yuan, a year-on-year decrease of 74.52%. The basic earnings per share were 0.25 yuan

    Zhitong·
    SH
    600129
    +0.37%
    Zhitong·
    SH
    600129
    +0.37%

    TAIJI GROUP: Obtained a commitment letter for stock repurchase loans from financial institutions

    On the evening of August 14th, TAIJI GROUP announced that it recently received a "Loan Commitment Letter" issued by the Chongqing Branch of China Merchants Bank, with a loan commitment amount not exceeding 108 million yuan, a financing term of 3 years, and the loan purpose being a special loan for stock repurchase

    Zhitong·
    SH
    600129
    +0.37%
    Zhitong·
    SH
    600129
    +0.37%
    © 2025 Longbridge｜Disclaimer